Psilocybin News to Pay Attention to While $SHRM Shares are Locked

We featured $SHRM early on when it began trading, and investors who bought in had an opportunity to book significant profits over the past month, but now the future is uncertain, with stock halted at $0.89 since June 19th, 2020. Investors are waiting for the company to submit Business Acquisition Reports (BARs) for Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. However, of bigger concern is what the ‘continuous disclosure review’ (CDR) could mean for the company, as it is likely the regulators will dig deep into the pricing of the stock deals, and possibly the marketing materials used for them. Depending on the outcome of the review, it is possible that the halt won’t just be a week, but could be a month or more.

If we learned one thing from the Marijuana stock rollercoaster ride from 2015-2020, it’s that in the early stages of any new, growing sector, there are many ups and downs. From 2015-2017, there were more non-believers in marijuana than believers, but once the ship took off, everyone wanted to be on board. Those who positioned themselves early in the stocks with strong, smart management teams won big.

Regardless of what happens with $SHRM, the psychedelic drug space should prove its worth in the coming years. The market potential for psychedelic treatments is vast, and if certain stocks fall off, new leaders will emerge from the pack. If you currently have money locked in $SHRM, here are some events to focus on while you wait for it to begin trading again:

  1. Therapsil is an organization with the goal of helping terminally ill patients accept mortality without fear, through psilocybin assisted therapy. We have previously noted the potential for Psilocybin to help terminally ill patients, referring to the, Johns Hopkins University research study in 2016 conducted by Roland Griffiths and his colleagues, that resulted in relief for end-of-life distress in 80% of the cancer patients who participated. The use of psilocybin to aid the mental health of terminal patients could add another segment to a psilocybin market already forecasted to be massive. If Therapsil’s research confirms the study conducted by Johns Hopkins, we would expect the FDA to consider this use case, with many other countries following suit. Learn more at www.therapsil.ca
  2. The U.S. Department of Defense announced last week that its Defense Advanced Research Projects Agency (DARPA), is investing $26.9 million USD to “create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects,” in coordination with the University of North Carolina (UNC) School of Medicine. Bryan L. Roth, a professor of pharmacology at UNC School of Medicine was quoted, “Our team has developed innovative methods and technologies to overcome these limitations with the goal of creating better medications to treat these neuropsychiatric conditions.”  Psilocybin and Ketamine were both named specifically, but the study aims to produce similar compounds, ideally without the hallucinogenic effects. This public funding effort is not associated with the $17 million USD Johns Hopkins psychedelic research centre announce in the US in September of 2019, testing psychedelics to treat conditions such as opioid use disorder, Alzheimer’s disease, depression, anxiety and PTSD. “Depression, anxiety, and substance abuse affect large segments of the population,” Roth said. “Rapidly acting drugs with antidepressant, anti-anxiety, and anti-addictive potential devoid of disabling side effects do not exist, not even as experimental compounds for use in animals. Creating such compounds would change the way we treat millions of people around the world suffering from these serious and life-threatening conditions.” Stanford University, the Icahn School of Medicine at Mt. Sinai, the University of California at San Francisco and Duke University will all participate in the research study.
  3. We noted that on June 26th, Liberty Leaf changed its name to Nova Mentis, and began trading as $NOVA on the CSE. Yahoo Finance published the story July 6th. A notable excerpt from the article, featured the specific research studies being conducted by $NOVA “(Nova Mentis) will aim to understand how psilocybin modulates the gut-brain axis and effects on metabolic and mental health. Dr. Mohammadi also will explore subjects of chronic low-grade inflammation, or systemic inflammation, investigating alterations in the microbiome and intestinal barrier function. There are direct and indirect pathways of communication between the gut and the brain. The Vagus nerve, for example, connects the gut to the brain, working in both directions, sending messages, and receiving them. Nova Mentis aims to understand the therapeutic potential of activating these and other receptors with psilocybin in the “second brain” that lives in the gut, the enteric nervous system.” The article continued, noting the possibility of reclassifying psilocybin as a result of the studies, “Within the coming years, in the event that psilocybin is reclassified from Schedule 1 to perhaps Schedule 3 or 4, or even one day legalized, the early movers in the space should reap the benefits. Psychedelic stocks look to be the next wave, with over $320 million of funding raised in 2019 and 2020 to date.”

As the race to definitively prove the positive effects of psilocybin continues in 2020, we thought we’d end this update highlighting some important trends that we track from searches on the internet.

  • The ratio of searches for “Magic Mushrooms” vs “Psilocybin” has decreased from about 7:1 in 2010, to 4:1 in 2020, which we believe to be a positive indicator for the science and medicinal case for the molecule.
  • Daily google searches with the word “psilocybin” have been consistently increasing since 2017, as can be seen in the chart below:

The right questions are increasingly being asked online:

  • “What psilocybin taught me about dying” is the second most “what psilocybin” term searched on the internet in 2020, whereas prior to the Johns Hopkins’ study in 2016, it didn’t make the top 5 list.
  • “Why Psilocybin should be legalized” is the top “why psilocybin” question asked on the in internet in 2020.
  • “Can psilocybin cure anxiety” is the second most searched “can psilocybin” question asked on internet searches in 2020.
  • “How psilocybin works” is the top “how psilocybin” question.

All these trends can be used by investors to gauge interest in this sector through websites like trends.google.com and answerthepublic.com

Share This: